Novel Explanted Human Liver Model to Assess Hepatic Extraction, Biliary Excretion and Transporter Function
© 2023 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics..
Realistic models predicting hepatobiliary processes in health and disease are lacking. We therefore aimed to develop a physiologically relevant human liver model consisting of normothermic machine perfusion (NMP) of explanted diseased human livers that can assess hepatic extraction, clearance, biliary excretion, and drug-drug interaction (DDI). Eleven livers were included in the study, seven with a cirrhotic and four with a noncirrhotic disease background. After explantation of the diseased liver, NMP was initiated. After 120 minutes of perfusion, a drug cocktail (rosuvastatin, digoxin, metformin, and furosemide; OATP1B1/1B3, P-gp, BCRP, and OCT1 model compounds) was administered to the portal vein and 120 minutes later, a second bolus of the drug cocktail was co-administered with perpetrator drugs to study relevant DDIs. The explanted livers showed good viability and functionality during 360 minutes of NMP. Hepatic extraction ratios close to in vivo reported values were measured. Hepatic clearance of rosuvastatin and digoxin showed to be the most affected by cirrhosis with an increase in maximum plasma concentration (Cmax ) of 11.50 and 2.89 times, respectively, compared with noncirrhotic livers. No major differences were observed for metformin and furosemide. Interaction of rosuvastatin or digoxin with perpetrator drugs were more pronounced in noncirrhotic livers compared with cirrhotic livers. Our results demonstrated that NMP of human diseased explanted livers is an excellent model to assess hepatic extraction, clearance, biliary excretion, and DDI. Gaining insight into pharmacokinetic profiles of OATP1B1/1B3, P-gp, BCRP, and OCT1 model compounds is a first step toward studying transporter functions in diseased livers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:114 |
|---|---|
| Enthalten in: |
Clinical pharmacology and therapeutics - 114(2023), 1 vom: 14. Juli, Seite 137-147 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stevens, Lianne J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.06.2023 Date Revised 20.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cpt.2905 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355466791 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355466791 | ||
| 003 | DE-627 | ||
| 005 | 20231226064414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cpt.2905 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355466791 | ||
| 035 | |a (NLM)37042227 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stevens, Lianne J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel Explanted Human Liver Model to Assess Hepatic Extraction, Biliary Excretion and Transporter Function |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.06.2023 | ||
| 500 | |a Date Revised 20.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. | ||
| 520 | |a Realistic models predicting hepatobiliary processes in health and disease are lacking. We therefore aimed to develop a physiologically relevant human liver model consisting of normothermic machine perfusion (NMP) of explanted diseased human livers that can assess hepatic extraction, clearance, biliary excretion, and drug-drug interaction (DDI). Eleven livers were included in the study, seven with a cirrhotic and four with a noncirrhotic disease background. After explantation of the diseased liver, NMP was initiated. After 120 minutes of perfusion, a drug cocktail (rosuvastatin, digoxin, metformin, and furosemide; OATP1B1/1B3, P-gp, BCRP, and OCT1 model compounds) was administered to the portal vein and 120 minutes later, a second bolus of the drug cocktail was co-administered with perpetrator drugs to study relevant DDIs. The explanted livers showed good viability and functionality during 360 minutes of NMP. Hepatic extraction ratios close to in vivo reported values were measured. Hepatic clearance of rosuvastatin and digoxin showed to be the most affected by cirrhosis with an increase in maximum plasma concentration (Cmax ) of 11.50 and 2.89 times, respectively, compared with noncirrhotic livers. No major differences were observed for metformin and furosemide. Interaction of rosuvastatin or digoxin with perpetrator drugs were more pronounced in noncirrhotic livers compared with cirrhotic livers. Our results demonstrated that NMP of human diseased explanted livers is an excellent model to assess hepatic extraction, clearance, biliary excretion, and DDI. Gaining insight into pharmacokinetic profiles of OATP1B1/1B3, P-gp, BCRP, and OCT1 model compounds is a first step toward studying transporter functions in diseased livers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Rosuvastatin Calcium |2 NLM | |
| 650 | 7 | |a 83MVU38M7Q |2 NLM | |
| 650 | 7 | |a Furosemide |2 NLM | |
| 650 | 7 | |a 7LXU5N7ZO5 |2 NLM | |
| 650 | 7 | |a ATP Binding Cassette Transporter, Subfamily G, Member 2 |2 NLM | |
| 650 | 7 | |a Neoplasm Proteins |2 NLM | |
| 650 | 7 | |a Membrane Transport Proteins |2 NLM | |
| 650 | 7 | |a Metformin |2 NLM | |
| 650 | 7 | |a 9100L32L2N |2 NLM | |
| 650 | 7 | |a Digoxin |2 NLM | |
| 650 | 7 | |a 73K4184T59 |2 NLM | |
| 700 | 1 | |a Dubbeld, Jeroen |e verfasserin |4 aut | |
| 700 | 1 | |a Doppenberg, Jason B |e verfasserin |4 aut | |
| 700 | 1 | |a van Hoek, Bart |e verfasserin |4 aut | |
| 700 | 1 | |a Menke, Aswin L |e verfasserin |4 aut | |
| 700 | 1 | |a Donkers, Joanne M |e verfasserin |4 aut | |
| 700 | 1 | |a Alsharaa, Abdulnaser |e verfasserin |4 aut | |
| 700 | 1 | |a de Vries, Arjan |e verfasserin |4 aut | |
| 700 | 1 | |a Vaes, Wouter H J |e verfasserin |4 aut | |
| 700 | 1 | |a Knibbe, Catherijne A J |e verfasserin |4 aut | |
| 700 | 1 | |a van de Steeg, Evita |e verfasserin |4 aut | |
| 700 | 1 | |a Alwayn, Ian P J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical pharmacology and therapeutics |d 1960 |g 114(2023), 1 vom: 14. Juli, Seite 137-147 |w (DE-627)NLM000015318 |x 1532-6535 |7 nnns |
| 773 | 1 | 8 | |g volume:114 |g year:2023 |g number:1 |g day:14 |g month:07 |g pages:137-147 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cpt.2905 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 114 |j 2023 |e 1 |b 14 |c 07 |h 137-147 | ||